Ipsen SA
Ipsen is a French biopharmaceutical company headquartered in Paris, France, with a focus on drug development and commercialization in three therapeutic areas: oncology, rare diseases and neuroscience. Ipsen is one of the world's top 15 biopharmaceutical companies in terms of oncology sales.
Filings
54 filings
- Ipsen provides update on Phase III BOLD trial in biliary atresiaInside informationFR
- Ipsen announces the launch of an Employee Shareholding PlanInside informationFR
- Annual General Meeting of Ipsen S.A. held on 13 May 2026Inside information
- Assemblée Générale Annuelle d’Ipsen S.A. du 13 mai 2026Inside informationFrench
- Ipsen S.A. – Evolution of the composition of the Board of DirectorsInside information
- Ipsen S.A. – Evolution de la composition du Conseil d’administrationInside informationFrench
- Ipsen S.A. publishes its 2025 Consolidated Financial StatementsInside information
- Ipsen nominates Peter Guenter to its Board of DirectorsInside informationFR
- Ipsen provides update on legacy of Henri BeaufourInside informationFR
- Communication relative à l'actionnariat d'IpsenInside informationFrench
- Ipsen S.A. - Initiation of the share buy-back programInside informationFR
- Ipsen S.A. - Annual General Meeting held on 21 May 2025Inside informationFR
- Ipsen announces issuance of €500 million inaugural Rated Public BondInside informationFR
- Ipsen S.A. publishes its 2024 consolidated financial statementsInside information
About
- ISIN
- FR0010259150
- Ticker
- IPN
- LEI
- 549300M6SGDPB4Z94P11
- Sector
- Health care
- Founded
- 1929
- Employees
- 5,300
- Country of registration
- FR
- Last filing
- 03/08/2026, 18:00
Description from Wikidata, CC0 licence.
Filing history
Filings per month
28
Sept 23May 24Jan 25Sept 25Aug 26
Document types
Across the whole archive